Description
A combination vial pairing BPC-157 with TB-500 (thymosin beta-4) in equal amounts: 5mg + 5mg, 10mg + 10mg or 15mg + 15mg. It is used in tissue-repair research that studies both peptides together.
10 vials per box. Strengths are per vial; prices are per box.
Research summaries
Complementary mechanisms in soft-tissue models
BPC-157 and thymosin beta-4 have been studied through distinct mechanisms — FAK-paxillin signalling and growth-factor modulation for BPC-157, and actin-binding, cell-migration and angiogenic activity for thymosin beta-4. Preclinical repair studies of each compound report improved healing endpoints across tendon, muscle and wound models.
The two peptides are combined in research because they appear to act on different parts of the repair process. Direct combination trials are scarce; the pairing is a protocol convention, not a proven synergy.
For research use only. Not for human or veterinary use.
